Companies · Other Health Care

Avedro Inc

WALTHAM · Other Health Care

Diligence memoA one-page analyst read on Avedro Inc — recommendation, valuation, rhythm, risks.
$158.4M
Total raised · real
8
Rounds
2.1×
Latest step-up
Top 3%
Sector rank · raised
Series C
Latest stage · inferred · Thu Apr 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Avedro Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.55× the median modeled value of Series C Other Health Care companies in 2016–2018 (40 peers) — value vs value, same stage and era.
Dormant
  • Last raise 8.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Avedro Inc is one of 5376 Other Health Care companies tracked from WALTHAM. By capital raised it ranks among the largest (ahead of 98% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
19
Investors (latest)
2018-04-26
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2009-04-29 Raised $10M (real) Modeled valuation $202M (est)Series A2009Series A · 2010-07-14 Raised $6.3M (real) Modeled valuation $127M (est)Series A2010Series A · 2010-07-14 Raised $13M (real) Modeled valuation $268M (est)Series A2010Series A · 2010-07-14 Raised $4.6M (real) Modeled valuation $92M (est)Series A2010Series B · 2011-06-30 Raised $26M (real) Modeled valuation $577M (est)Series B2011Series B · 2011-06-30 Raised $26M (real) Modeled valuation $566M (est)Series B2011Series C · 2013-03-01 Raised $42M (real) Modeled valuation $957M (est)Series C2013Series A · 2014-11-05 Raised $6.5M (real) Modeled valuation $131M (est)Series A2014Series C · 2014-11-05 Raised $14M (real) Modeled valuation $313M (est)Series C2014Series C · 2015-11-13 Raised $17M (real) Modeled valuation $378M (est)Series C2015Series C · 2017-04-17 Raised $12M (real) Modeled valuation $274M (est)Series C2017Series C · 2018-04-26 Raised $25M (real) Modeled valuation $572M (est)Series C2018Cumulative $201M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$10.0M · 2009
Series A extension$6.3M · 2010
Series A extension$13.3M · 2010
Series A extension$4.6M · 2010
Series B$26.0M · 2011
Series B extension$25.5M · 2011
Series C$41.9M · 2013
Bridge · Series C-stage$6.5M · 2014smaller follow-on
Series C extension$13.7M · 2014
Series C extension$16.5M · 2015
Series C extension$12.0M · 2017
Series C extension$25.0M · 2018

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 60%.

Modeled valuation trajectory
$571.6M
Base estimate est.
$90.9M
Conservative case
$1.5B
Upside case
$166.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $201.8M · 2009-04-292009Series A · modeled $127.0M · 2010-07-14Series A · modeled $267.7M · 2010-07-14Series A · modeled $92.4M · 2010-07-14Series B · modeled $576.7M · 2011-06-30Series B · modeled $565.6M · 2011-06-30Series C · modeled $957.4M · 2013-03-01Series A · modeled $131.2M · 2014-11-05Series C · modeled $313.1M · 2014-11-05Series C · modeled $378.0M · 2015-11-13Series C · modeled $274.4M · 2017-04-17Series C · modeled $571.6M · 2018-04-262018
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
6.0 yr
Elapsed time used
8.2 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
10 mo
Avg between rounds
$17.6M/yr
Capital velocity
17.2 yr
On record since
2009
First round
12
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 65× above median
This company$158.4M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.5× of median
This company$25.0M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 26× above median
This company$571.6M
Sector median$22.1M

Raised more than 98% of sector peers (real $). Modeled value above 94% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #33 of 40.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Specialty Networks, LLC · Series C Raised $94.5M · modeled $2.2B (est)New MMI Holdings, Inc. · Series C Raised $80.7M · modeled $1.8B (est)BioMatrix Holdings, L.L.C. · Series C Raised $80.0M · modeled $1.8B (est)Sea Hunter Holdings, LLC · Series C Raised $76.3M · modeled $1.7B (est)Bind Benefits, Inc. · Series C Raised $70.0M · modeled $1.6B (est)Endotronix Inc · Series C Raised $116.1M · modeled $1.6B (est)Great Basin Scientific, Inc. · Series C Raised $124.3M · modeled $1.6B (est)TransMedics, Inc. · Series C Raised $249.0M · modeled $1.5B (est)Landmark Health, LLC · Series C Raised $90.8M · modeled $1.4B (est)Rapid Micro Biosystems, Inc. · Series C Raised $134.6M · modeled $1.4B (est)Mdp Acm Holdings, Llc · Series C Raised $60.0M · modeled $1.4B (est)ACON BioMatrix Investors I, L.L.C. · Series C Raised $57.5M · modeled $1.3B (est)Avedro Inc (this company) Raised $158.4M · modeled $571.6M (est)Avedro Inc
CompanyStageRaised · realValue · estvs peer med.
Specialty Networks, LLCSeries C$94.5M$2.2B2.08×
New MMI Holdings, Inc.Series C$80.7M$1.8B1.77×
BioMatrix Holdings, L.L.C.Series C$80.0M$1.8B1.76×
Sea Hunter Holdings, LLCSeries C$76.3M$1.7B1.68×
Bind Benefits, Inc.Series C$70.0M$1.6B1.54×
Endotronix IncSeries C$116.1M$1.6B1.52×
Great Basin Scientific, Inc.Series C$124.3M$1.6B1.49×
TransMedics, Inc.Series C$249.0M$1.5B1.40×
Landmark Health, LLCSeries C$90.8M$1.4B1.34×
Rapid Micro Biosystems, Inc.Series C$134.6M$1.4B1.32×
Mdp Acm Holdings, LlcSeries C$60.0M$1.4B1.32×
ACON BioMatrix Investors I, L.L.C.Series C$57.5M$1.3B1.26×
Avedro Inc this companySeries C$158.4M$571.6M0.55×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$10.0M2009-04-29$45.5M$201.8M85%
Series A$6.3M2010-07-14$28.6M$127.0M85%
Series A$13.3M2010-07-14$60.3M$267.7M85%
Series A$4.6M2010-07-14$20.8M$92.4M85%
Series B$26.0M2011-06-30$144.6M$576.7M85%
Series B$25.5M2011-06-30$141.8M$565.6M85%
Series C$41.9M2013-03-01$279.2M$957.4M85%
Series A$6.5M2014-11-05$29.5M$131.2M85%
Series C$13.7M2014-11-05$91.3M$313.1M85%
Series C$16.5M2015-11-13$110.2M$378.0M85%
Series C$12.0M2017-04-17$80.0M$274.4M90%
Series C$25.0M2018-04-26$166.7M$571.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$10.0M2009-04-29
    • First recorded raise — entered as Series A.
    • 10 investors on this round.
  2. Series A$6.3M2010-07-14
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 1.6× smaller than the prior — bridge or down round.
    • 15 investors on this round.
  3. Series A$13.3M2010-07-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.1× larger than the prior — scaling up.
    • 15 investors on this round.
  4. Series A$4.6M2010-07-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.9× smaller than the prior — bridge or down round.
    • 10 investors on this round.
  5. Series B$26.0M2011-06-30
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 5.7× larger than the prior — scaling up.
    • 23 investors on this round.
  6. Series B$25.5M2011-06-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 22 investors on this round.
  7. Series C$41.9M2013-03-01
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
    • 18 investors on this round.
  8. Series A$6.5M2014-11-05
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 6.4× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 21 investors on this round.
  9. Series C$13.7M2014-11-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.1× larger than the prior — scaling up.
    • 22 investors on this round.
  10. Series C$16.5M2015-11-13
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 23 investors on this round.
  11. Series C$12.0M2017-04-17
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
    • 14 investors on this round.
  12. Series C$25.0M2018-04-26
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 2.1× larger than the prior — scaling up.
    • 19 investors on this round.
Intelligence
2019 ~Q1
Modeled next raise · ~10mo cadence
$52.1M
Modeled next size est.range $33.9M$83.3M
2.1×
Last step-up
$17.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Garheng Kong15 other2018-04
Jonathan Silverstein9 other2018-04
Reza Zadno6 other2018-04
Doug Cole5 other2009-04
Philip J. Ferneau5 other2009-04
Anthony J. Natale4 other2009-04
Gilbert H. Kliman4 other2017-04
Joseph Mandato4 other2009-04
Gilbert Kliman3 other2018-04
Hongbo Lu3 other2018-04
Robert J. Palmisano2 other2014-11
Robert Palmisano2 other2018-04
David J. Berry1 other2014-11
Jason J. Hong1 other2013-03
Reza H Zadno1 other2017-04
Brian J. Roberts2014-11
David F. Muller2009-04
David J. Mayer2013-03
Donald Zurbay2018-04
Doug Carl Cole2010-07
Jeff J. Dykan2011-06
JONATHAN H. SILVERSTEIN2017-04
JOSEPH H. MANDATO2017-04
Joseph J. Mandato2010-07
Registry & provenance

Avedro Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1343304
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Autonomic Technologies IncOther Health CareSeries C$125.6M$1.1Bnetwork2 shared operators · same sector · same stage
Venus Concept Inc.Other Health CareSeries C$194.2M$9.8Mnetwork1 shared operator · same sector · same stage
NeuroPace IncOther Health CareSeries C$208.6M$1.5Bnetwork1 shared operator · same sector · same stage
Spirox, Inc.Other Health CareSeries C$98.2M$1.0Bnetwork1 shared operator · same sector · same stage
Vavotar Life Sciences LLCOther Health CareSeries C$156.0M$228.6Msame sector · same stage
Transcend Medical IncOther Health CareSeries B$122.3M$648.4Mnetwork1 shared operator · same sector
Exo Imaging, Inc.Other Health CareSeries C$169.6M$284.4Msame sector · same stage
Direct Flow Medical, Inc.Other Health CareSeries C$170.5M$619.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Aveta.Life Inc.Other Health CareSeed$41.3M89%
Avex, LlcOther Health CareSeries A$152.3M87%
SCA Aventura Holdings, LLCOther Health CarePre-Seed$2.5M85%
Avela Health, IncHealthtechSeries A$18.6M84%
Atreo, Inc.Other Health CareSeed$42.1M83%
UpHealth, Inc.Other Health CareSeries A$34.7M83%
Avertix Medical, Inc.HealthtechSeries B$4.7M82%
AngelMD, Inc.Other Health CareSeries A$245.0M82%
Frequently asked
How much funding has Avedro Inc raised?
Avedro Inc has raised approximately $158.4M in disclosed capital across 8 recorded financing rounds, aggregated from public filings.
What is Avedro Inc's estimated valuation?
Provath's modeled valuation for Avedro Inc is approximately $571.6M (modeled range $90.9M–$1.5B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Avedro Inc at?
Avedro Inc's latest modeled financing stage is Series C. Its most recent recorded round closed around Thu Apr 26.
What does Avedro Inc do and where is it based?
Avedro Inc operates in the Other Health Care sector, based in WALTHAM.
Explore related

See where Avedro Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Avedro Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.